October 3, 2011 – Boston Scientific has enrolled the first patients in its NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) clinical trial. NECTAR-HF is a prospective, randomized, international clinical feasibility study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients. The study will evaluate 96 patients with vagal nerve stimulator implants at multiple centers in Europe.

September 30, 2011 – Cambridge Heart Inc. announced its HearTwave II System was cleared for sale by the Mexican regulatory authorities. In August 2010, the company executed an exclusive distribution agreement with Mayerick S.A. de S.V. to distribute the system, including the company’s microvolt t-wave alternans (MTWA) software and micro-V alternans sensors. This addition represents the company’s first distribution agreement in Latin America.

September 30, 2011 — Boston Scientific Corp. said the U.S. Court of Appeals for the Federal Circuit found in favor of the company in a 1998 stent patent infringement suit involving Johnson & Johnson.

September 28, 2011 — The 24th annual International Symposium on Endovascular Therapy (ISET) will take place Jan. 15-19, 2012, at the Fontainebleau Miami Beach. More than 1,500 members of the global endovascular community will be in attendance; this includes physicians, researchers, scientists, biomedical engineers, nurses, technologists and other industry professionals. The fields of interventional radiology, interventional cardiology and vascular surgery will be represented, among others.

September 28, 2011 –Ziehm Imaging said its holding company Aton GmbH acquired 100 percent of the United States-based mini C-arm specialist OrthoScan Inc.